For a young female with autoimmune encephalitis who did not improve with high‑dose IV methylprednisolone but responded to IVIG, what is the preferred bridging therapy?

Bridging Therapy After IVIG Response in Autoimmune Encephalitis

For a patient with autoimmune encephalitis who failed IV methylprednisolone but responded to IVIG, the preferred bridging therapy is monthly IVIG infusions, with oral prednisone taper as an alternative option. 1

Rationale for IVIG as Preferred Bridging Therapy

Since your patient demonstrated clear clinical improvement with IVIG but not with corticosteroids, continuing the therapy that worked (IVIG) makes the most clinical sense. The 2021 consensus guidelines explicitly state bridging therapy options include "gradual oral prednisone taper or monthly intravenous Ig or intravenous methylprednisolone." 1

Why IVIG Over Steroids in This Case:

• Treatment response pattern matters: Your patient's lack of response to IV methylprednisolone suggests steroid-resistant disease, making oral prednisone taper a less logical choice
• IVIG advantages: No psychiatric side effects, no increased thromboembolism risk (except line-related), and better tolerability in agitated patients 1
• Proven efficacy: Monthly IVIG maintains therapeutic antibody clearance and immune modulation established during acute treatment

Practical Implementation

Monthly IVIG Protocol:

• Dosing: Typically 2 g/kg divided over 2-5 days per month
• Duration: Continue for at least 6-12 months, then reassess based on clinical stability and antibody titers
• Monitoring: Track clinical symptoms, cognitive function, and seizure frequency

If IVIG is Not Feasible (access, cost, or tolerability issues):

Consider oral prednisone taper as second-line bridging:

• Start at 1 mg/kg/day (maximum 60-80 mg)
• Taper gradually over 3-6 months
• Monitor for steroid side effects (hyperglycemia, hypertension, psychiatric symptoms, osteoporosis)

Critical Considerations for Long-Term Management

You must also plan for maintenance immunotherapy, not just bridging. The survey data from the same guidelines shows 46% of experts prefer rituximab as maintenance therapy for antibody-mediated autoimmune encephalitis. 2

When to Consider Second-Line Agents:

If the patient experiences:

• Relapse during bridging therapy: Consider rituximab (preferred for antibody-mediated disease like NMDAR, LGI1, CASPR2)
• Second relapse: 70% of experts recommend maintenance immunosuppression for neuronal surface antibody-positive cases 2
• Persistent symptoms after 2-4 weeks of combined first-line therapy: Escalate to rituximab or cyclophosphamide 1

Common Pitfalls to Avoid

1. Don't switch to steroids just because they're easier: Your patient already demonstrated steroid resistance—respect that treatment response pattern
2. Don't stop immunotherapy too early: Premature discontinuation leads to relapse; bridging therapy typically requires 6-12 months minimum
3. Don't forget tumor surveillance: Continue cancer screening appropriate for the antibody type (if identified) and clinical presentation
4. Monitor for treatment complications: IVIG can cause aseptic meningitis, hemolysis, and renal dysfunction; check renal function and hemoglobin before each infusion

Antibody-Specific Considerations

If antibody results become available:

• NMDAR-antibody encephalitis: Strongly favor IVIG bridging followed by rituximab maintenance 1
• LGI1-antibody encephalitis: Recent data suggests combination therapy (IVIG + lower-dose steroids) may be optimal, but given steroid failure, continue IVIG alone 3
• Seronegative cases: IVIG remains appropriate; 61% of experts recommend maintenance therapy after second relapse even without identified antibodies 2